Gilead Sciences Sees Institutional Investment Boost

Jackson Square Capital LLC acquires over 8,400 shares of the biopharmaceutical company

Apr. 9, 2026 at 10:53am

Got story updates? Submit your updates here. ›

An extreme close-up of gleaming, intricate banking machinery and equipment, conveying the secure, powerful infrastructure of the financial industry without using any text or symbols.Gilead Sciences' robust institutional backing signals the biopharmaceutical firm's continued strength and stability in the financial markets.Foster City Today

Jackson Square Capital LLC, an institutional investor, acquired a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to a recent SEC filing. The firm purchased 8,451 shares of the biopharmaceutical company's stock, valued at approximately $1,037,000.

Why it matters

This investment by a major institutional player highlights the continued interest and confidence in Gilead Sciences from the financial community. As a leading biopharmaceutical firm, Gilead's stock performance and institutional backing are closely watched indicators of the company's health and future prospects.

The details

According to the filing, Jackson Square Capital LLC was one of several large investors that made moves in Gilead Sciences stock during the fourth quarter. Other firms, such as West Paces Advisors Inc., BIP Wealth LLC, and Greenleaf Trust, also boosted their positions in the company. Overall, institutional investors now own 83.67% of Gilead Sciences' outstanding shares.

  • The SEC filing detailing Jackson Square Capital's new position in Gilead Sciences was made in the fourth quarter of 2026.

The players

Jackson Square Capital LLC

An institutional investment firm that acquired a new position in Gilead Sciences, Inc. during the fourth quarter of 2026.

Gilead Sciences, Inc.

A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, including antiviral therapies for HIV and viral hepatitis.

Got photos? Submit your photos here. ›

The takeaway

The investment by Jackson Square Capital and other institutional players underscores the continued confidence in Gilead Sciences' financial performance and growth potential within the biopharmaceutical industry. This influx of institutional backing could help drive further stock appreciation and solidify Gilead's position as a leading player in the sector.